Psychiatry, Internal medicine, Antipsychotic, Schizophrenia and Olanzapine are his primary areas of study. His research in Psychiatry intersects with topics in Meta-analysis and Randomized controlled trial. His Internal medicine study combines topics in areas such as Relapse prevention, Placebo, Ziprasidone and Mania.
His work is dedicated to discovering how Antipsychotic, Clinical trial are connected with Cognition, Psychotherapist and Health services research and other disciplines. His Schizophrenia study combines topics from a wide range of disciplines, such as Psychosis, Severity of illness and Psychometrics. His Olanzapine study incorporates themes from Quetiapine and Haloperidol.
His primary scientific interests are in Psychiatry, Internal medicine, Antipsychotic, Schizophrenia and Meta-analysis. In his research, Cognition is intimately related to Clinical psychology, which falls under the overarching field of Psychiatry. The various areas that Stefan Leucht examines in his Internal medicine study include Placebo and Olanzapine.
His work carried out in the field of Olanzapine brings together such families of science as Quetiapine, Risperidone and Aripiprazole. His Antipsychotic research is multidisciplinary, incorporating elements of Discontinuation, Haloperidol, Relapse prevention, Number needed to treat and Pharmacology. His Schizophrenia research integrates issues from Psychosis, Medical prescription and Rating scale.
Stefan Leucht mostly deals with Internal medicine, Antipsychotic, Schizophrenia, Meta-analysis and Randomized controlled trial. He has included themes like Placebo, Psychosis, Positive and Negative Syndrome Scale and Clozapine in his Internal medicine study. The Antipsychotic study combines topics in areas such as Olanzapine, Reduction and Confidence interval.
His research integrates issues of Dopamine, Neuroscience and Rating scale in his study of Schizophrenia. His work deals with themes such as Psychological intervention, Psychiatry, Bioinformatics, Tolerability and Fluoxetine, which intersect with Meta-analysis. His Text mining research extends to Psychiatry, which is thematically connected.
Stefan Leucht spends much of his time researching Internal medicine, Meta-analysis, Antipsychotic, Randomized controlled trial and Schizophrenia. His studies deal with areas such as Risperidone, Placebo and Psychosis, Positive and Negative Syndrome Scale as well as Internal medicine. His Meta-analysis research incorporates themes from Clinical trial, Schizophrenia, Psychiatry, Fluoxetine and Sertraline.
He studies Antipsychotic, namely Amisulpride. His Randomized controlled trial research is multidisciplinary, incorporating elements of Quetiapine, Major depressive disorder and Brief Psychiatric Rating Scale. The concepts of his Schizophrenia study are interwoven with issues in Endocrinology, Effects of sleep deprivation on cognitive performance, Striatum and Dihydroxyphenylalanine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht;Andrea Cipriani;Andrea Cipriani;Loukia Spineli;Dimitris Mavridis.
The Lancet (2013)
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht;Caroline Corves;Caroline Corves;Dieter Arbter;Rolf R Engel.
The Lancet (2009)
Physical illness in patients with severe mental disorders.I. Prevalence, impact of medications and disparities in health care
Marc De Hert;Christoph U. Correll;Julio Bobes;Marcelo Cetkovich-Bakmas.
World Psychiatry (2011)
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
Andrea Cipriani;Andrea Cipriani;Toshi A Furukawa;Georgia Salanti;Anna Chaimani;Anna Chaimani;Anna Chaimani.
The Lancet (2018)
What does the PANSS mean
Stefan Leucht;Stefan Leucht;John M. Kane;Werner Kissling;Johannes Hamann.
Schizophrenia Research (2005)
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
S. Leucht;G. Pitschel-Walz;D. Abraham;W. Kissling.
Schizophrenia Research (1999)
The Effect of Family Interventions on Relapse and Rehospitalization in Schizophrenia—A Meta-analysis
Gabi Pitschel-Walz;Stefan Leucht;Josef Bäuml;Werner Kissling.
Schizophrenia Bulletin (2001)
Opioid antagonists for alcohol dependence
Susanne Rösner;Andrea Hackl‐Herrwerth;Stefan Leucht;Simona Vecchi.
Cochrane Database of Systematic Reviews (2010)
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
Stefan Leucht;Magdolna Tardy;Katja Komossa;Stephan Heres.
The Lancet (2012)
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
Marc De Hert;Dan Cohen;Julio Bobes;Marcelo Cetkovich-Bakmas.
World Psychiatry (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: